BioMarin Pharmaceutical Statistics
Share Statistics
BioMarin Pharmaceutical has 190.58M shares outstanding. The number of shares has increased by 1.01% in one year.
| Shares Outstanding | 190.58M |
| Shares Change (YoY) | n/a |
| Shares Change (QoQ) | 0.11% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 188.22M |
| Failed to Deliver (FTD) Shares | 2 |
| FTD / Avg. Volume | 0% |
Short Selling Information
The latest short interest is 5.21M, so 2.73% of the outstanding shares have been sold short.
| Short Interest | 5.21M |
| Short % of Shares Out | 2.73% |
| Short % of Float | 2.77% |
| Short Ratio (days to cover) | 3.44 |
Valuation Ratios
The PE ratio is 108.03 and the forward PE ratio is 22.12. BioMarin Pharmaceutical 's PEG ratio is 0.21.
| PE Ratio | 108.03 |
| Forward PE | 22.12 |
| PS Ratio | 7.49 |
| Forward PS | 3.6 |
| PB Ratio | 3.66 |
| P/FCF Ratio | 350.66 |
| PEG Ratio | 0.21 |
Enterprise Valuation
BioMarin Pharmaceutical Inc. has an Enterprise Value (EV) of 18.49B.
| EV / Earnings | 110.29 |
| EV / Sales | 7.64 |
| EV / EBITDA | 59.59 |
| EV / EBIT | 95.09 |
| EV / FCF | 357.99 |
Financial Position
The company has a current ratio of 2.51, with a Debt / Equity ratio of 0.22.
| Current Ratio | 2.51 |
| Quick Ratio | 1.57 |
| Debt / Equity | 0.22 |
| Total Debt / Capitalization | 18.12 |
| Cash Flow / Debt | 0.15 |
| Interest Coverage | 11.22 |
Financial Efficiency
Return on equity (ROE) is 0.03% and return on capital (ROIC) is 2.86%.
| Return on Equity (ROE) | 0.03% |
| Return on Assets (ROA) | 0.02% |
| Return on Capital (ROIC) | 2.86% |
| Revenue Per Employee | 711.33K |
| Profits Per Employee | 49.29K |
| Employee Count | 3.40K |
| Asset Turnover | 0.35 |
| Inventory Turnover | 0.52 |
Taxes
| Income Tax | 20.92M |
| Effective Tax Rate | 0.11 |
Stock Price Statistics
The stock price has increased by -31.76% in the last 52 weeks. The beta is 0.31, so BioMarin Pharmaceutical 's price volatility has been higher than the market average.
| Beta | 0.31 |
| 52-Week Price Change | -31.76% |
| 50-Day Moving Average | 65.77 |
| 200-Day Moving Average | 77.52 |
| Relative Strength Index (RSI) | 38.38 |
| Average Volume (20 Days) | 1.44M |
Income Statement
In the last 12 months, BioMarin Pharmaceutical had revenue of 2.42B and earned 167.65M in profits. Earnings per share was 0.89.
| Revenue | 2.42B |
| Gross Profit | 1.84B |
| Operating Income | 194.44M |
| Net Income | 167.65M |
| EBITDA | 310.28M |
| EBIT | 194.44M |
| Earnings Per Share (EPS) | 0.89 |
Balance Sheet
The company has 755.13M in cash and 1.10B in debt, giving a net cash position of -340.62M.
| Cash & Cash Equivalents | 755.13M |
| Total Debt | 1.10B |
| Net Cash | -340.62M |
| Retained Earnings | -621.55M |
| Total Assets | 6.85B |
| Working Capital | 2.34B |
Cash Flow
In the last 12 months, operating cash flow was 159.26M and capital expenditures -107.61M, giving a free cash flow of 51.65M.
| Operating Cash Flow | 159.26M |
| Capital Expenditures | -107.61M |
| Free Cash Flow | 51.65M |
| FCF Per Share | 0.27 |
Margins
Gross margin is 76.15%, with operating and profit margins of 8.04% and 6.93%.
| Gross Margin | 76.15% |
| Operating Margin | 8.04% |
| Pretax Margin | 7.79% |
| Profit Margin | 6.93% |
| EBITDA Margin | 12.83% |
| EBIT Margin | 8.04% |
| FCF Margin | 2.13% |
Dividends & Yields
BMRN does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | 1.4% |
| FCF Yield | 0.42% |
Analyst Forecast
The average price target for BMRN is $90, which is 41.1% higher than the current price. The consensus rating is "Buy".
| Price Target | $90 |
| Price Target Difference | 41.1% |
| Analyst Consensus | Buy |
| Analyst Count | 21 |
Scores
| Altman Z-Score | 6.28 |
| Piotroski F-Score | 6 |